NSE: BIOCON · 26 October 2026
- Biocon Limited shares traded higher on Monday, gaining 0.51% to settle at ₹325.15 compared to its previous close of ₹323.50. The stock moved within a relatively narrow intraday band, hitting a high of ₹328.20 and a low of ₹321.40 after opening slightly softer at ₹322.20.
- The company entered into a global settlement and license agreement with Genentech to resolve pending patent disputes, securing licensed launch dates for Pebrilzo, its biosimilar to Perjeta. The agreement permits launches in the European Union and UK in the first quarter of calendar year 2027, the U.S. in the third quarter of calendar year 2028, and across other international markets between 2026 and 2028.
- Trading volume was 0.23 times the 20-day average daily volume.
Why is Biocon Limited. share price rising on 26 October 2026?
Biocon Limited shares traded higher on Monday, gaining 0.51% to settle at ₹325.15 compared to its previous close of ₹323.50. The stock moved within a relatively narrow intraday band, hitting a high of ₹328.20 and a low of ₹321.40 after opening slightly softer at ₹322.20.
In the broader market context, the stock's modest gain outperformed the benchmark Nifty index, which rose by 0.10%, while aligning with strength in the Nifty Pharma sector index, which advanced 0.81%. Despite today's mild recovery, Biocon has experienced notable downward pressure over recent weeks, posting a 5-day return of -6.89% and a 20-day return of -15.98%, trading not far above its 52-week low of ₹318.40.
The price movement coincides with the company's recent announcement on October 26, 2026, confirming a license agreement with Janssen Sciences Ireland to commercialize Yesintek, its proposed biosimilar to Stelara, across additional global markets including Australia, Brazil, China, and South Korea.
6.06 lakh shares traded by 26 October 2026 · 10:35 AM IST. This compares with a 20-day average daily volume of 26.13 lakh shares (0.23 times). The five-day average daily volume was 26.32 lakh shares. Separately, the NSE report for 23 October 2026 showed 18.25 lakh shares delivered, representing 52.58% of that day’s traded volume. The same report recorded 51,014 trades.
The stock moved up modestly by 0.51% amid light trading volumes that ran well below average. While recent strategic announcements regarding global biosimilar market expansions provide positive background, today's price action appears primarily aligned with sector-wide tailwinds in pharmaceutical stocks following an extended period of downward retracement.
Latest Company Developments
The company entered into a global settlement and license agreement with Genentech to resolve pending patent disputes, securing licensed launch dates for Pebrilzo, its biosimilar to Perjeta. The agreement permits launches in the European Union and UK in the first quarter of calendar year 2027, the U.S. in the third quarter of calendar year 2028, and across other international markets between 2026 and 2028.
Clearing global patent litigation provides clear execution timelines and visibility for the future rollout of a major oncology biosimilar.
a press release dated September 08, 2026, titled "Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil".
a press release dated September 21, 2026, titled "Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach".
Communication regarding remittance of final dividend for the FY 2025-26.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 22.08% on 30 September 2026. This compares with 15.47% on 30 June 2026, a change of +6.61 percentage points.
The filing reported 40 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution progress and regulatory timelines for the commercialization of Yesintek across newly secured global markets.
- Developments regarding the upcoming rollout milestones for Pebrilzo following the Genentech patent settlement.
- Delivery volume trends and cash market participation relative to the 20-day average volume of 606,008 shares.
- Price stabilization around the 52-week low support level of ₹318.40.
Other Dated Coverage
- Biocon Limited. Share Price Today: Why BIOCON Is Falling 2.06% | 23 October 2026 — 23 October 2026
- Biocon in Focus After Global Patent Settlement for Pebrilzo | 15 October 2026 — 15 October 2026
- Biocon Limited. Share Price Today: Why BIOCON Is Rising 0.82% | 14 October 2026 — 14 October 2026
More Biocon Limited. news and dated analysis →
Frequently Asked Questions
What is the latest Biocon Limited. company news?
The company entered into a global settlement and license agreement with Genentech to resolve pending patent disputes, securing licensed launch dates for Pebrilzo, its biosimilar to Perjeta. The agreement permits launches in the European Union and UK in the first quarter of calendar year 2027, the U.S. in the third quarter of calendar year 2028, and across other international markets between 2026 and 2028.
How strong was Biocon Limited.’s trading volume?
6.06 lakh shares traded, 0.23 times the 20-day average daily volume. The price and volume data are dated 26 October 2026 · 10:35 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.